Estrella Immunopharma (ESLA) Cash from Financing Activities (2021 - 2026)
Estrella Immunopharma (ESLA) posted quarterly Cash from Financing Activities of $7.2 million for Q1 2026, up 24677.8% year-over-year from N/an in Q1 2025, and up 11270.94% quarter-over-quarter from -$64821.0 in Q4 2025.
Estrella Immunopharma (ESLA) Cash from Financing Activities (2021 - 2026) Analysis & Trends
Estrella Immunopharma (ESLA) has reported Cash from Financing Activities for 6 consecutive years, with $7.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 24677.8% year-over-year to $7.2 million; the TTM figure through Mar 2026 stood at $9.5 million (up 1030.23% YoY), while the FY2025 annual figure was $2.3 million, up 560.35% from the prior year.
- Cash from Financing Activities grew to $7.2 million in Q1 2026 per ESLA's latest filing, from -$64821.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $20.0 million in Q3 2023 and bottomed at -$36.1 million in Q4 2022.
- Historically, Cash from Financing Activities has averaged $473002.6 across 5 years, with a median of $78535.5 in 2023.
- Annual changes were most pronounced in 2024 — Cash from Financing Activities slumped 192.53% — and 2026, when it jumped 24677.8%.
- Estrella Immunopharma's Cash from Financing Activities stood at -$36.1 million in 2022, then jumped by 137.86% to $13.7 million in 2023, then sank by 100.99% to -$134986.0 in 2024, then surged by 51.98% to -$64821.0 in 2025, then jumped by 11270.94% to $7.2 million in 2026.
- Business Quant data shows ESLA's Cash from Financing Activities at $7.2 million in Q1 2026, -$64821.0 in Q4 2025, and $1.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Estrella Immunopharma | 32.29 Mn | 32.14 Mn | - | 4.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.00 |
| Jun 30, 2026 | 4.00 |
| Mar 31, 2026 | 7.24 Mn |
| Mar 31, 2026 | 7.24 Mn |
| Dec 31, 2025 | -64,821.00 |
| Dec 31, 2025 | -64,821.00 |
| Sep 30, 2025 | 1.04 Mn |
| Sep 30, 2025 | 1.04 Mn |
| Jun 30, 2025 | 1.31 Mn |
| Jun 30, 2025 | 1.31 Mn |
| Mar 31, 2025 | -29,462.00 |
| Mar 31, 2025 | -29,462.00 |
| Dec 31, 2024 | -134,986.00 |
| Dec 31, 2024 | -134,986.00 |
| Sep 30, 2024 | -504,905.00 |
| Sep 30, 2024 | -504,905.00 |
| Jun 30, 2024 | -354,440.00 |
| Jun 30, 2024 | -354,440.00 |
| Mar 31, 2024 | -84,091.00 |
| Mar 31, 2024 | -84,091.00 |